Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 5;29(7):1317–1331. doi: 10.1158/1078-0432.CCR-22-2274

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2023 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 6. Combination effects of lorlatinib and idasanutlin in ALK-altered neuroblastoma PDX models. A, GR-NB4 (B) IC-pPDX-112 (C) HSJD-NB-012 PDX models were treated with vehicle control, idasanutlin, lorlatinib, or idasanutlin and lorlatinib combination. I, Tumor volumes were monitored during treatment [with (A.ii) inset of GR-NB4 PDX up to day 10]. (A.iii, B.ii, and C.ii) pY1586/total ALK measured by immunoassay in tumor lysates taken at the end of the experiment (mean of two technical replicates). One-way ANOVA: A.iii: P = <0.0001; B.ii: P = 0.0331; C.ii: P = 0.0020. — Combination effects of lorlatinib and idasanutlin in ALK-altered neuroblastoma PDX models. GR-NB4 (A), IC-pPDX-112 (B), and HSJD-NB-012 (C) PDX models were treated with vehicle control, idasanutlin, lorlatinib, or idasanutlin and lorlatinib combination. (i) Tumor volumes were monitored during treatment [with (A.ii) inset of GR-NB4 PDX up to day 10]. (A.iii, B.ii, and C.ii) pY1586/total ALK measured by immunoassay in tumor lysates taken at the end of the experiment (mean of two technical replicates). One-way ANOVA: A.iii: P = <0.0001; B.ii: P = 0.0331; C.ii: P = 0.0020.